Latest IPOs
| Deutsche Bank cuts Teva to Hold |
| Teva Pharmaceutical Industries remains Deutsche Bank's favorite in the generic drugs sphere, just to be clear about that. Even so, the bank downgraded its fave from Buy to Hold after the Israeli company admitted its failure to prove that a doubled dose |
More
-
UPDATE 2-Blockbuster swings to profit in first quarter
Net profit was $45.4 million, or 20 cents per share, for its fiscal first quarter ended April 6, compared with a year-earlier loss of $49 million or 27 cents per share.
-
American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes (PR Newswire)
American Oriental Bioengineering, Inc. today announced its intention to offer, subject to market conditions and other factors, $85 million aggregate principal amount of Convertible Senior Notes due 2015 to qualified institutional buyers in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended .